Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women
Authors:
- 1 October 2005
- journal article
- research article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 28 (9) , 623-631
Abstract
The aim of our prospective, randomised, controlled and open-label clinical study was to evaluate in healthy post-menopausal women the effects of raloxifene (RLX) on body fat distribution and lipids, and the correlations between these parameters. The fat distribution, by dual energy X-ray absorptiometry, and lipids were evaluated at baseline and after 1 yr in 50 postmenopausal women: 25 were treated with RLX 60 mg/die, while 25 served as control group (CG). After 1 yr, we observed in RLX-users a slight reduction of fat mass in trunk and central region and an increase in legs and, in relation to CG, significantly lower values of adiposity in trunk and abdominal region (ppp<0.05). No correlation was underlined among lipids and regional fat distribution. These results highlight the positive effect of RLX on lipids and suggest, for the first time, that RLX promotes the shift from android to gynoid fat distribution, and prevents the uptrend of abdominal adiposity and body weight compared with untreated women.Keywords
This publication has 56 references indexed in Scilit:
- Differential Effects of Raloxifene and Estrogen on Insulin Sensitivity in Postmenopausal WomenJournal of the American Geriatrics Society, 2003
- Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 studyClimacteric, 2001
- Raloxifene and estrogen reduces progression of advanced atherosclerosis — a study in ovariectomized, cholesterol-fed rabbitsAtherosclerosis, 2001
- Effect of menopausal status on body composition and abdominal fat distributionInternational Journal of Obesity, 2000
- Relationships between abdominal body fat distribution and cardiovascular risk factors: an explanation for women’s healthier cardiovascular risk profile. The D.E.S.I.R. StudyInternational Journal of Obesity, 1999
- Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized TrialJournal of Bone and Mineral Research, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Influence of age and menopause on serum lipids and lipoproteins in healthy womenAtherosclerosis, 1993
- Menopause and Risk Factors for Coronary Heart DiseaseNew England Journal of Medicine, 1989
- Fat cell metabolism in different regions in women. Effect of menstrual cycle, pregnancy, and lactation.Journal of Clinical Investigation, 1985